BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21555363)

  • 1. Cost-utility and expected value of perfect information related to trabectedin in the treatment of metastatic soft-tissue sarcoma: the publicly funded comments explored.
    Soini EJ
    Ann Oncol; 2011 Jun; 22(6):1465-1466. PubMed ID: 21555363
    [No Abstract]   [Full Text] [Related]  

  • 2. Trabectedin in the treatment of metastatic soft-tissue sarcoma: cost-effectiveness and cost-utility are yet to be proved.
    Blomqvist C; Johansson R; Tarkkanen M
    Ann Oncol; 2011 Apr; 22(4):988. PubMed ID: 21345940
    [No Abstract]   [Full Text] [Related]  

  • 3. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information.
    Soini EJO; García San Andrés B; Joensuu T
    Ann Oncol; 2011 Jan; 22(1):215-223. PubMed ID: 20627875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
    Simpson EL; Rafia R; Stevenson MD; Papaioannou D
    Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.
    Rafia R; Simpson E; Stevenson M; Papaioannou D
    Pharmacoeconomics; 2013 Jun; 31(6):471-8. PubMed ID: 23568332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Foreword.
    Reichardt P
    Future Oncol; 2015; 11(11 Suppl):1. PubMed ID: 26043309
    [No Abstract]   [Full Text] [Related]  

  • 7. Trabectedin in advanced soft tissue sarcoma: case series.
    Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
    J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
    Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575
    [No Abstract]   [Full Text] [Related]  

  • 9. Trabectedin in soft tissue sarcomas.
    Petek BJ; Loggers ET; Pollack SM; Jones RL
    Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?
    Assi T; Cesne AL
    Future Oncol; 2023 Sep; 19(28):1893-1896. PubMed ID: 37781755
    [No Abstract]   [Full Text] [Related]  

  • 11. Trabectedin: novel insights in the treatment of advanced sarcoma.
    Lopez JP; Gajdos C; Elias A
    Curr Oncol Rep; 2014 Jun; 16(6):387. PubMed ID: 24756367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabectedin for the treatment of relapsed ovarian cancer.
    Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
    Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
    Gordon EM; Sankhala KK; Chawla N; Chawla SP
    Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin for the management of soft-tissue sarcoma.
    Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
    Le Cesne A; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin's contribution to the treatment of sarcomas.
    Blay JY
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
    Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
    Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In brief: Two Drugs for soft-tissue sarcoma.
    Med Lett Drugs Ther; 2016 May; 58(1494):e62. PubMed ID: 27148925
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.